Yet another reason I’m skeptical of Ozempic and the like. As if the warning about thyroid cancer weren’t enough, now there’s this, and there is zero mention of it on the website for Ozempic.
Novo Nordisk, the Ozempic manufacturer, says in the article, “drugs in this class have been used for 15 years to treat diabetes and for eight years to treat obesity.” My understanding was this didn’t even come on the market until 2012, so maybe I’m not understanding what they mean by “this class.”
What bothers me most is that I’m having stomach issues regarding Ozempic, and when I requested to change meds, my doctor requested that I reduce my dosage instead. Combined with unrelated issues with my doctor, this phrase from the article rings true for me: “doctors dismissed.” I feel dismissed. As I write this, I can feel the surge of adrenaline in my arms, realizing I’m ready to confront my doctor.
I have a lot of questions and suspicions about why Ozempic and its siblings are being pushed so hard. Certainly, anti-fat bias is a major component. However, it always comes back to money . . . which is what my next blog post will discuss.